ACRO BIOMEDICAL CO., LTD.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-101.1K | $-42.3K | $-8.8M | $-15.9M | $-7.7M | $-117.5K | $-371.6K | $419.7K |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $0 | $8.1M | $15.7M | $7.7M | $0 | $148.4K | $7.4K |
| Net Cash from Operating Activities | $-196.3K | $-36.7K | $-15.4K | $-147.5K | $299.3K | $-199.5K | $-59.7K | $-140.4K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $199.9K | $36.8K | $10.0K | $58.1K | $-222.2K | $216.7K | $23.0K | $104.8K |
| Net Change in Cash | — | — | — | — | — | $17.2K | $-36.7K | $-35.7K |
| Free Cash Flow | — | — | — | — | — | — | — | — |